| Name | Title | Contact Details |
|---|
Equipment Planning Associates Limited is a Richmond Hill, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Forten Corporation is a Poway, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 1988 in Queensbury, N.Y., U.S., AngioDynamics is today a NASDAQ-listed public company. We are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. Our diverse product line includes market-leading radiofrequency ablation and NanoKnife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. AngioDynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. AngioDynamics believes it is well poised to continue that trend. Looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patient care by providing the highest-quality, best-performing products.
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company`s first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable. Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO.
Still River Systems is dedicated to providing physicians and their patients access to high quality, cost-effective proton therapy solutions, and to helping establish this superior treatment modality as a standard of care for patients worldwide.